Hangzhou Polymed Biopharmaceuticals Inc. has synthesized IL-1 receptor-associated kinase 4 (IRAK-4) and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer.
Research at Humanwell Healthcare (Group) Co. Ltd. has led to the identification of interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Researchers from Hangzhou Polymed Biopharmaceuticals Inc. have reported the discovery and preclinical evaluation of HPB-092, an FMS-like tyrosine kinase 3 (FLT3) and interleukin-1 receptor-associated kinase 4 (IRAK-4) dual inhibitor, being developed for the treatment of acute myeloid leukemia (AML).
Dana-Farber Cancer Institute Inc. has synthesized IL-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
